In a similar published study, Choi et al. reported that CRISPR-Cas9 disruption of PD-1 enhances the activity of second-generation EvCAR-T cells under the control of CD3zeta and 4-1BB signaling molecules in a preclinical model of human GBM [38]. The gene discussed is CD247; the disease is glioblastoma.